Dompé On A Roll After Securing A “Yes” Under The UK’s Early Access Scheme
Executive Summary
Just weeks after the European Medicines Agency recommended that Dompé’s neurotrophic keratitis treatment Oxervate be authorized for sale, the company has received the all clear to make the product available to patients in the UK before its formal approval by the European Commission. Meanwhile, the Italian company is working on targeting the US and Japanese markets too.
You may also be interested in...
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.
English Funding For Aquipta Targets AbbVie’s Migraine Drug To 170,000 People
Aquipta is the first oral treatment that NICE has recommended for preventing chronic migraines in the fourth-line setting, and the second oral treatment for episodic migraines in the same setting. The drug has already secured reimbursement in Scotland, Sweden and Israel.
Quotable: Top Experts On Policy Hot Topics
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.